Men who had a high genetic risk of developing prostate cancer were less likely to develop a lethal form of the disease if they maintained a healthy lifestyle, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.
17th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
The Victoria’s Secret Global Fund for Women’s Cancers was established to accelerate innovation in cancer research for women, by women.
Overview The 12th Annual Symposium on Global Cancer Research (ASGCR) will be held virtually May 6 – May 9, 2024 [8AM-12PM Eastern Time each day]. See…
FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases Date: May 9, 2024 | 9:00 a.m. – 4:00 p.m. Location:…
FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases Date: May 9, 2024 | 9:00 a.m. – 4:00 p.m. Location:…
On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months
AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
These three-year grants of $450,000 support creative, paradigm-shifting cancer research that may not be funded through conventional channels.
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.
